Renal Cancer - Results from #2000

Prognostic Role of Circulating Tumor Cells (CTCS) in Metastatic Renal Cell Carcinoma: A Large, Multicenter Prospective Trial. June 4, 2021

Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. June 4, 2021

Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. June 3, 2021

Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma. June 3, 2021

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. June 2, 2021

High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab. June 2, 2021

American Urological Association (AUA) Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer June 1, 2021

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). June 1, 2021

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. June 1, 2021

Retroperitoneal versus transepritoneal robot-assisted partial nephrectomy for postero-lateral renal masses: an international multicenter analysis. May 31, 2021

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. May 31, 2021

Three-dimensional Coculture Provides an Improved in Vitro Model for Papillary Renal Cell Carcinoma. May 28, 2021

Propofol inhibits the proliferation, migration, invasion and epithelial to mesenchymal transition of renal cell carcinoma cells by regulating microRNA-363/Snail1. May 28, 2021

Combining Stereotactic Body Radiotherapy and Microwave Ablation Appears Safe and Feasible for Renal Cell Carcinoma in an Early Series. May 27, 2021

Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma. May 27, 2021

Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. May 26, 2021

NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway. May 26, 2021

Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients. May 25, 2021

Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses. May 25, 2021

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. May 25, 2021

Page 101 of 456